Next-Generation QACs.
Hard on Pathogens.
Easy on People and Planet.
Embedded Files
The Mission
Science-led. Evidence-driven. Impact-focused.
Science-led. Evidence-driven. Impact-focused.
We are developing a new class of olefinic quaternary ammonium compounds (oQACs): patent‑protected, next‑generation QACs that combine broad‑spectrum, anti‑biofilm antimicrobial activity with reduced toxicity and environmental persistence.
Designed for versatility, these molecules have the potential to function as low‑dose preservatives and high‑performance surface sanitisers, while their improved safety profile opens a path toward future topical therapeutic use on skin and mucosal surfaces.
Our current data come from preclinical models, and further studies and regulatory review will be required before any clinical or commercial use.
The Team
The Team
Dr Alan Cameron
Dr Alan Cameron
Co-Founder | Chemistry
A specialist in organic and medicinal chemistry, Alan is a co-inventor of our technology and leads the scientific development of OleQuat’s next-generation oQAC platform. His research background bridges synthetic chemistry and practical formulation design, with a focus on creating safer, more effective compounds.
Dr Kristi Biswas
Dr Kristi Biswas
Co-Founder | Microbiology
Kristi is a microbiologist with deep expertise in bacterial biofilms and infection dynamics. She drives OleQuat’s biological validation and testing programmes. Her work underpins the scientific evidence for our oQACs' performance in a range of applications.
Craig Squire
Craig Squire
Co-Founder | Commercial and CEO
Craig brings a decade of experience investing in and working with start-up ventures and complex technologies in New Zealand. At OleQuat he oversees commercial strategy, partnerships, and capital development, connecting world-class science with real-world impact across multiple sectors.
Contact Us
If our oQACs sound interesting to you, get in touch. We'd love to hear from you.
craig@olequat.com
Page updated
Report abuse